Equity Details
Price & Market Data
Price: $1.17
Daily Change: -$0.01 / 0.85%
Daily Range: $1.09 - $1.19
Market Cap: $75,153,440
Daily Volume: 894,222
Performance Metrics
1 Week: -4.96%
1 Month: 12.75%
3 Months: 15.40%
6 Months: 5.50%
1 Year: -16.06%
YTD: 15.00%
About TScan Therapeutics, Inc. (TCRX)
Get immediate market data for TScan Therapeutics, Inc. (TCRX). Price: 1.17, daily change: -$0.01 / 0.85%. Market cap: 75,153,440. All performance metrics at your fingertips.
Company Details
Employees: 142
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.